Medico Remedies LimitedMEDICOCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Dec 2025 1 quarters of data

₹22.03

MCap ₹183 Cr

Medico Remedies Limited — Stock analysis & AI research Medico Remedies Limited — Multibagger AI analysis Medico Remedies Limited — Seasonality — best & worst months Medico Remedies Limited — Technical setup — score, trend, support & resistance Medico Remedies Limited — Live exchange announcements

📈 RSI Oversold Stocks 📈 MACD Bullish Crossover 📈 Lowest Technical Score 📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹59 Cr

Sales · Dec 2025

₹4 Cr

Operating Profit · Dec 2025

7.4%

OPM % · Dec 2025

₹3 Cr

Net Profit · Dec 2025

₹0.35

EPS · Dec 2025

📝 Medico Remedies Limited — results explained

Quarter ended December 2025 (Q3 FY26)

Medico Remedies Limited reported revenue of ₹59 crore for the quarter ended December 2025 (Q3 FY26).

Net profit stood at ₹3 crore. Earnings per share (EPS) came in at ₹0.35.

Operating profit stood at ₹4 crore — an operating margin (OPM) of 7.4%.

Valuation snapshot

At the current price of ₹22.03, MEDICO has a market capitalisation of ₹183 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 61.38%, foreign institutional investors (FIIs) 0.60%, public shareholders 38.02% of Medico Remedies Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹183 Cr

Current Price ?

₹22.0

P/E ?

N/A

Industry P/E ?

37.20

P/B ?

2.41

P/S ?

N/A

P/FCF ?

182.81

Enterprise Value ?

₹202 Cr

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

23.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹59 Cr

PAT — latest qtr ?

₹3 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹19 Cr

Debt to Equity ?

0.25

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

61.38%

Change in promoter holding ?

-1.21%

Pledged percentage ?

N/A

Market

Return 3 months ?

-43.2%

Return 6 months ?

-46.6%

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Dec bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Dec 2025	YoY %	QoQ %
Sales	59	—	—
Operating Profit	4	—	—
Other Income	1	—	—
Interest	0	—	—
Depreciation	1	—	—
Profit Before Tax	4	—	—
Net Profit	3	—	—
EPS	0.35	—	—
OPM %	7.4%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	17	17	17	17	+0.0%
Reserves	27	36	46	59	+28.3%
Borrowings	10	8	15	19	+26.7%
Other Liabilities	34	36	43	59	+37.2%
Total Liabilities	87	96	120	153	+27.5%
Fixed Assets	22	21	21	20	-4.8%
CWIP	0	-0	0	3	—
Investments	1	2	2	2	+0.0%
Other Assets	64	73	96	129	+34.4%
Total Assets	87	96	120	153	+27.5%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	8	2	5	6	+20.0%
Cash from Investing Activity	-7	-3	-3	-5	-66.7%
Cash from Financing Activity	-2	-0	-1	-1	+0.0%
Net Cash Flow	-0	-1	1	1	+0.0%
Free Cash Flow	2	-0	2	1	-50.0%
CFO/OP	111%	43%	58%	64%	+10.3%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	94	125	138	145	+5.1%
Inventory Days	69	54	90	72	-20.0%
Days Payable	108	105	117	119	+1.7%
Cash Conversion Cycle	54	75	111	98	-11.7%
Working Capital Days	54	74	90	87	-3.3%
ROCE %	21%	21%	21%	23%	+9.5%

👥 Shareholding (latest 6 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026	% Chg
Promoters	62.59%	61.38%	61.38%	61.38%	61.38%	61.38%	+0.0%
FIIs	0.07%	0.30%	0.49%	0.03%	0.08%	0.60%	+650.0%
DIIs	0.01%	0.01%	0.00%	0.00%	—	—	—
Public	37.33%	38.30%	38.13%	38.60%	38.54%	38.02%	-1.3%
No. of Shareholders	16,474	18,503	16,562	16,189	15,863	17,716	+11.7%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	MEDICO Medico Remedies	₹34.59	287	20.7	238	14	7.4%	5.8%	29.5%	1.1%	81.4%	38.5%

❓ Frequently asked questions

What was Medico Remedies Limited's revenue in Q3 FY26?